文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

甲状腺全切术和选择性颈淋巴结清扫术而未接受放射性碘治疗的 T1N0M0 单发甲状腺乳头状癌患者具有良好的预后。

Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy.

机构信息

Department of Surgery, Kuma Hospital, 8-2-35, Shimoyamate-dori, Chuo-ku, Kobe City, 650-0011, Japan.

出版信息

World J Surg. 2010 Jun;34(6):1285-90. doi: 10.1007/s00268-009-0356-0.


DOI:10.1007/s00268-009-0356-0
PMID:20041244
Abstract

BACKGROUND: The extent of surgery for papillary carcinoma significantly differs between western countries and Japan. Almost routine total thyroidectomy with radioiodine ablation therapy has been performed in western countries, whereas limited thyroidectomy has been adopted in Japan, especially for low-risk cases. In this study, the prognosis of patients with solitary papillary carcinoma measuring 2 cm or less without massive extrathyroid extension, clinically apparent lymph node metastasis or distant metastasis at diagnosis (T1N0M0 in the UICC TNM classification) was investigated to elucidate the appropriate extent of surgery for these patients. METHODS: We investigated the prognosis of 2,638 patients with solitary T1N0M0 papillary carcinoma who underwent initial surgery between 1987 and 2004. Total or near total thyroidectomy was performed for 1,037 patients and the remaining 1,601 patients underwent more limited thyroidectomy. Elective central node dissection was performed for 2,511 patients, accounting for 96%, and 1,545 (59%) also underwent prophylactic lateral node dissection. Radioiodine ablation therapy was performed only for three patients. RESULTS: The 10-year disease-free survival (DFS) rate of our series was 97%. To date, recurrence was observed in 62 patients (2%) and 41 showed recurrence to the regional lymph nodes. Seventeen of 1,601 patients who received limited thyroidectomy (1%) showed recurrence to the remnant thyroid. Pathological nodal-positive patients showed a worse DFS, but the 10-year DFS rate was still high at 96%. Patients with total or near total thyroidectomy had a better DFS, but the difference disappeared if recurrence to the remnant thyroid was excluded. A number needed to treat (NNT) for total or near total thyroidectomy over hemithyroidectomy was 83 to prevent 1 recurrence. CONCLUSIONS: These findings suggest that solitary T1N0M0 patients have an excellent prognosis when they undergo thyroidectomy and elective lymph node dissection without radioiodine therapy. Regarding the extent of thyroidectomy, hemithyroidectomy is adequate for these patients, if a 1% risk of recurrence to the remnant thyroid is accepted.

摘要

背景:西方国家和日本在甲状腺乳头状癌的手术范围上存在显著差异。在西方国家,几乎常规进行全甲状腺切除术和放射性碘消融治疗,而在日本则采用有限的甲状腺切除术,特别是对于低危病例。在这项研究中,我们研究了诊断时无大量甲状腺外侵犯、临床明显淋巴结转移或远处转移(UICC TNM 分类中的 T1N0M0)的 2cm 或以下单发甲状腺乳头状癌患者的预后,以阐明这些患者的适当手术范围。

方法:我们调查了 1987 年至 2004 年间接受初始手术的 2638 例单发 T1N0M0 甲状腺乳头状癌患者的预后。1037 例患者接受了全甲状腺或近全甲状腺切除术,其余 1601 例患者接受了更有限的甲状腺切除术。2511 例患者选择性进行中央淋巴结清扫术,占 96%,其中 1545 例(59%)还预防性进行侧方淋巴结清扫术。仅对 3 例患者进行放射性碘消融治疗。

结果:本研究系列的 10 年无病生存率(DFS)为 97%。迄今为止,62 例(2%)患者出现复发,41 例复发至区域淋巴结。在接受有限甲状腺切除术的 1601 例患者中,有 17 例(1%)出现残余甲状腺复发。淋巴结阳性患者的 DFS 较差,但 10 年 DFS 率仍高达 96%。全甲状腺或近全甲状腺切除术患者的 DFS 更好,但如果排除残余甲状腺复发,则差异消失。全甲状腺或近全甲状腺切除术相对于半甲状腺切除术预防 1 例复发的治疗需要数(NNT)为 83。

结论:这些发现表明,对于接受甲状腺切除术和选择性淋巴结清扫术而不进行放射性碘治疗的单发 T1N0M0 患者,预后良好。对于甲状腺切除术的范围,如果接受残余甲状腺复发 1%的风险,半甲状腺切除术对这些患者是足够的。

相似文献

[1]
Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy.

World J Surg. 2010-6

[2]
Excellent prognosis of patients with solitary T1N0M0 papillary thyroid carcinoma who underwent thyroidectomy and elective lymph node dissection without radioiodine therapy.

World J Surg. 2011-1

[3]
Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment?

World J Surg Oncol. 2014-5-20

[4]
Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.

Minerva Endocrinol. 2013-9

[5]
Excellent Prognosis of Central Lymph Node Recurrence-Free Survival for cN0M0 Papillary Thyroid Carcinoma Patients Who Underwent Routine Prophylactic Central Node Dissection.

World J Surg. 2018-8

[6]
[Prospective therapy study in differentiated thyroid carcinoma].

Schweiz Med Wochenschr. 1995-11-18

[7]
Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.

J Clin Endocrinol Metab. 1997-11

[8]
Robotic total thyroidectomy with modified radical neck dissection via unilateral retroauricular approach.

Ann Surg Oncol. 2014-11

[9]
The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.

Cancer. 1998-1-15

[10]
Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.

Head Neck. 2015-9

引用本文的文献

[1]
Transcriptome sequencing revealed that lymph node metastasis of papillary thyroid microcarcinoma is associated with high THBS4 expression and PDGFRA+ cancer-associated fibroblasts.

Front Oncol. 2025-4-15

[2]
The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.

Endocr J. 2025-5-7

[3]
Study Protocol of Expanded Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Microcarcinoma (MAeSTro-EXP).

Endocrinol Metab (Seoul). 2025-4

[4]
Lobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary Thyroid Carcinoma.

JAMA Otolaryngol Head Neck Surg. 2025-2-1

[5]
Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma.

Ann Nucl Med. 2024-9

[6]
PAPILLARY MICROCARCINOMA OF THE THYROID GLAND - DOES SIZE MATTER?

Acta Endocrinol (Buchar). 2023

[7]
Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.

World J Surg. 2023-10

[8]
Migration of Risk Classification Between the JAES Versus ATA guidelines for Papillary Thyroid Carcinoma.

World J Surg. 2023-7

[9]
Risk factors for the lateral cervical lymph node metastasis of papillary thyroid carcinoma: A clinical study.

Mol Clin Oncol. 2023-2-15

[10]
Lymph node ratio is superior to AJCC N stage for predicting recurrence in papillary thyroid carcinoma.

Endocr Connect. 2022-2-16

本文引用的文献

[1]
Biological behavior and prognosis of familial papillary thyroid carcinoma.

Surgery. 2009-1

[2]
Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.

Surgery. 2008-12

[3]
Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.

Endocr J. 2009

[4]
Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping.

World J Surg. 2007-4

[5]
Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival.

World J Surg. 2006-5

[6]
Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma.

World J Surg. 2005-7

[7]
Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer.

World J Surg. 2005-4

[8]
Papillary microcarcinoma of the thyroid: how should it be treated?

World J Surg. 2004-11

[9]
An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid.

Thyroid. 2003-4

[10]
Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.

J Clin Endocrinol Metab. 2001-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索